An observational study in Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Mayo Clinic · Observational
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
This will be a cross sectional study and will include male and female, young (15-40-years) well characterized patients with early (eGFR>70mL/min/1.73m2) ADPKD. Patients with different classes of disease severity will be selected using the ADPKD imaging classification. The study will include 60 class-1 (A-E) patients (N=12 per each sub-class).
173 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 37 are open to participants now.
This study's planned enrollment of 60 is below the median of 150 across 43 observational studies indexed under Polycystic Kidney, Autosomal Dominant.
Browse Polycystic Kidney, Autosomal Dominant studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Male and female patients with a previous diagnosis of ADPKD
Exclusion Criteria:
Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
NOX4 levels
Determination of NOX4 levels from urine and plasma samples
Time frame: Baseline
mtDNA copy number
Determination of mtDNA copy number from urine and plasma samples
Time frame: Baseline
Tricarboxylic Acid (TCA) cycle metabolites
Determination of TCA cycle metabolite concentration from urine and plasma samples
Time frame: Baseline
REDOX status
Determination of REDOX from urine and plasma samples
Time frame: Baseline
Total kidney volume (TKV)
Determined by MRI
Time frame: Baseline
Estimated Glomerular Filtration Rate (eGFR)
Estimated by CKD-epi equation
Time frame: Baseline
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polycystic Kidney, Autosomal Dominant→
Mayo Clinic